Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Candida auris is an emerging fungal pathogen of great concern among the scientific community because it is causing an increasing number of hospital outbreaks of difficult management worldwide. In addition, isolates from this species frequently present reduced susceptibility to azole and echinocandin drugs. For this reason, it is necessary to develop new antifungal strategies to better control the disease caused by this yeast. In this work, we screened drugs from the Prestwick chemical library, which contains 1,280 off-patent compounds that are already approved by the Food and Drug Administration, with the aim of identifying molecules with antifungal activity against C. auris. In an initial screening, we looked for drugs that inhibited the growth of three different C. auris strains and found 27 of them which it did so. Ten active compounds were selected to test the susceptibility profile by using the EUCAST protocol. Antifungal activity was confirmed for seven drugs with MICs ranging from 0.5 to 64 mg/L. Some of these drugs were also tested in combination with voriconazole and anidulafungin at sub inhibitory concentrations. Our results suggest synergistic interactions between suloctidil and voriconazole with fractional inhibitory concentration index (FICI) values of 0.11 to 0.5 and between ebselen and anidulafungin (FICI, 0.12 to 0.44). Our findings indicate that drug repurposing could be a viable alternative to managing infections by C. auris.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 7×
“auris as pathogen was in 2009 when it was isolated from an external ear canal drainage from a patient in Japan (Satoh et al., 2009).”
BackgroundInfluentialFirst hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768 · cited 1×
“But in the last 5 years, this fungus has caused multiple hospital outbreaks worldwide (Calvo et al., 2016; Schelenz et al., 2016; Sharma et al., 2016; Chow et al., 2018; de Cassia Orlandi Sardi et al., 2018; Kohlenberg et al., 2018; Ruiz-Gaitan et al., 2018).”
BackgroundChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
White, R. L., Burgess, D. S., Manduru, M., & Bosso, J. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1914 · Cited by 721
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
A Candida auris Outbreak and Its Control in an Intensive Care Setting
Eyre, D. W., Sheppard, A. E., Madder, H., Moir, I., Moroney, R., Quan, T. P., Griffiths, D., George, S., Butcher, L., Morgan, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714373 · Cited by 517
Ruiz‐Gaitán, A., Moret, A. M., Tasias‐Pitarch, M., Aleixandre‐López, A. I., Martínez‐Morel, H., Calabuig, E., Salavert‐Lletí, M., Ramírez, P., López‐Hontangas, J. L., Hagen, F., et al. (2018) · Mycoses · doi:10.1111/myc.12781 · Cited by 343
Self-citationEchinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30597-8 · Cited by 289
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris
Chatterjee, S., Alampalli, S. V., Nageshan, R. K., Chettiar, S. T., Joshi, S., & Tatu, U. S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1863-z · Cited by 247
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
Multidrug-resistant Candida auris: ‘New kid on the block’ in hospital-associated infections?
Chowdhary, A., Voss, A., & Meis, J. F. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2016.08.004 · Cited by 214
Sharma, C., Kumar, N., Pandey, R., Meis, J. F., & Chowdhary, A. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.07.003 · Cited by 202
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Candida auris : An emerging multidrug-resistant pathogen
Sears, D., & Schwartz, B. S. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.08.017 · Cited by 146 · cited 2×
“auris antifungal susceptibility profile, most isolates are intrinsically resistant to fluconazole, and there is also a high resistance rate reported to echinocandins and amphotericin, limiting the treatment options that can be administered to patients (Lockhart et al., 2017b; Sears and Schwartz, 2017; Kordalewska et a…”
BackgroundSiles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-13 · Cited by 120 · cited 1×
“albicans and Cryptococcus neoformans (Butts et al., 2013; Siles et al., 2013; Kim et al., 2015; Wiederhold et al., 2017; Nixon et al., 2018).”
Butts, A., DiDone, L., Koselny, K., Baxter, B. K., Chabrier-Rosello, Y., Wellington, M., & Krysan, D. J. (2013) · Eukaryotic Cell · doi:10.1128/ec.00314-12 · Cited by 95
De Cremer, K., Lanckacker, E., Cools, T. L., Bax, M., De Brucker, K., Cos, P., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04229-14 · Cited by 77 · cited 1×
“Pyrvinium pamoate is synergistic with miconazole against C. albicans biofilms (De Cremer et al., 2015).”
BackgroundEpidemiology of invasive fungal diseases on the basis of autopsy reports
Dignani, M. C. (2014) · F1000Prime Reports · doi:10.12703/p6-81 · Cited by 73 · cited 1×
“Invasive fungal diseases (IFDs) have a high associated mortality rate and economic cost (Dignani, 2014; Drgona et al., 2014).”
BackgroundNew clinical phenotypes of fungal infections in special hosts
Pilmis, B., Puel, A., Lortholary, O., & Lanternier, F. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.05.016 · Cited by 68 · cited 1×
“Infections caused by fungi are an increasing threat for immunosuppressed patient, and their incidence has risen in the last few decades (Low and Rotstein, 2011; Brown et al., 2012; Pilmis et al., 2016).”
BackgroundRepurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kim, K., Zilbermintz, L., & Martchenko, M. (2015) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-015-0090-4 · Cited by 48
Cited by
Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110812 · Cited by 71
“com/ Candida species, Cryptococcus species, Saccharomyces cerevisiae, Aspergillus fumigatus, Fusarium oxysporum, Fusarium solani, Lichtheimia species, Lomentospora prolificans, Paecilomyces variotii, Rhizopus arrhizus, Scedosporium apiospermum [23,25,66,75,83,94,96,124, 165,228]”
BackgroundWall, G., Herrera, N., & Lopez-Ribot, J. L. (2019) · Journal of Fungi · doi:10.3390/jof5040092 · Cited by 58
Rossi, S. A., de Oliveira, H. C., Agreda-Mellon, D., Lucio, J., Mendes-Giannini, M. J. S., García-Cambero, J. P., & Zaragoza, O. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01921-19 · Cited by 48
“neoformans (26–28), the emerging pathogen Candida auris (26, 29, 30), and multiresistant molds such as Lomentospora prolificans (26).”
BackgroundSelf-citationSimm, C., Weerasinghe, H., Thomas, D. R., Harrison, P. F., Newton, H. J., Beilharz, T. H., & Traven, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00100-22 · Cited by 38
García-Barbazán, I., Torres-Cano, A., García-Rodas, R., Sachse, M., Luque, D., Megías, D., & Zaragoza, O. (2024) · mBio · doi:10.1128/mbio.02549-23 · Cited by 14
Metadata
- Authors
- de Oliveira, H. C., Monteiro, M. C., Rossi, S. A., Pemán, J., Ruiz-Gaitán, A., Mendes-Giannini, M. J. S., Mellado, E., & Zaragoza, O.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-02
- Volume
- 9
- Pages
- 83-83
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W2924389177
- Cited by
- 70
- References
- 24
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.